• Kalaris Therapeutics director and 10% owner Srinivas Akkaraju reported an indirect purchase of 244,300 common shares at USD 4.83.
• Samsara Opportunity Fund’s indirect stake rose to 2,224,147 shares.
• Samsara BioCapital reported an in-kind distribution that reduced its indirect holding by 66,906 shares to 10,657,028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-26-000532), on May 22, 2026, and is solely responsible for the information contained therein.